Terms: = Germ cell tumor AND RAF1, Raf-1, 5894, P04049, ENSG00000132155, c-Raf, CRAF AND Treatment
120 results:
1. CD133 significance in glioblastoma development: in silico and in vitro study.
Abdoli Shadbad M; Nejadi Orang F; Baradaran B
Eur J Med Res; 2024 Mar; 29(1):154. PubMed ID: 38448914
[TBL] [Abstract] [Full Text] [Related]
2. Relevance of detection of RAF fusion transcripts in pan-negative melanoma in routine practice.
Delzenne G; Boileau M; Jamme P; Farchi O; Mortier L
Melanoma Res; 2024 Apr; 34(2):182-185. PubMed ID: 38329225
[TBL] [Abstract] [Full Text] [Related]
3. miR-224-5p acts as a tumour suppressor and reverses the resistance to BRAF inhibitor in melanoma through directly targeting PAK4 to block the MAPK pathway.
Liu Y; Ruan H; Lu F; Peng H; Luan W
Pathol Res Pract; 2023 Sep; 249():154772. PubMed ID: 37611431
[TBL] [Abstract] [Full Text] [Related]
4. Artemisinin Confers Neuroprotection against 6-OHDA-Induced Neuronal Injury In Vitro and In Vivo through Activation of the ERK1/2 Pathway.
Li Q; Li S; Fang J; Yang C; Zhao X; Wang Q; Zhou W; Zheng W
Molecules; 2023 Jul; 28(14):. PubMed ID: 37513399
[TBL] [Abstract] [Full Text] [Related]
5. Targeting Prohibitins to Inhibit Melanoma Growth and Overcome Resistance to Targeted Therapies.
Najem A; Krayem M; Sabbah S; Pesetti M; Journe F; Awada A; Désaubry L; Ghanem GE
Cells; 2023 Jul; 12(14):. PubMed ID: 37508519
[TBL] [Abstract] [Full Text] [Related]
6. CircXPO1 Promotes Glioblastoma Malignancy by Sponging miR-7-5p.
Wang X; Wang J; An Z; Yang A; Qiu M; Tan Z
Cells; 2023 Mar; 12(6):. PubMed ID: 36980172
[TBL] [Abstract] [Full Text] [Related]
7. Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in
de Braud F; Dooms C; Heist RS; Lebbe C; Wermke M; Gazzah A; Schadendorf D; Rutkowski P; Wolf J; Ascierto PA; Gil-Bazo I; Kato S; Wolodarski M; McKean M; Muñoz Couselo E; Sebastian M; Santoro A; Cooke V; Manganelli L; Wan K; Gaur A; Kim J; Caponigro G; Couillebault XM; Evans H; Campbell CD; Basu S; Moschetta M; Daud A
J Clin Oncol; 2023 May; 41(14):2651-2660. PubMed ID: 36947734
[TBL] [Abstract] [Full Text] [Related]
8. Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of craf and MEK1/2.
Wang P; Jia X; Lu B; Huang H; Liu J; Liu X; Wu Q; Hu Y; Li P; Wei H; Liu T; Zhao D; Zhang L; Tian X; Jiang Y; Qiao Y; Nie W; Ma X; Bai R; Peng C; Dong Z; Liu K
Signal Transduct Target Ther; 2023 Mar; 8(1):96. PubMed ID: 36872366
[TBL] [Abstract] [Full Text] [Related]
9. Discovery of New Quinolone-Based Diarylamides as Potent B-RAF
Kim HJ; Park JW; Seo S; Cho KH; Alanazi MM; Bang EK; Keum G; El-Damasy AK
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834628
[TBL] [Abstract] [Full Text] [Related]
10. germline BRCA2 variants in advanced pancreatic acinar cell carcinoma: A case report and review of literature.
Lee CL; Holter S; Borgida A; Dodd A; Ramotar S; Grant R; Wasson K; Elimova E; Jang RW; Moore M; Kim TK; Khalili K; Moulton CA; Gallinger S; O'Kane GM; Knox JJ
World J Gastroenterol; 2022 Dec; 28(45):6421-6432. PubMed ID: 36533108
[TBL] [Abstract] [Full Text] [Related]
11. BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS
McGrail K; Granado-Martínez P; Esteve-Puig R; García-Ortega S; Ding Y; Sánchez-Redondo S; Ferrer B; Hernandez-Losa J; Canals F; Manzano A; Navarro-Sabaté A; Bartrons R; Yanes O; Pérez-Alea M; Muñoz-Couselo E; Garcia-Patos V; Recio JA
Nat Commun; 2022 Nov; 13(1):7113. PubMed ID: 36402789
[TBL] [Abstract] [Full Text] [Related]
12. RREB1 promotes the development of parafollicular carcinogenesis through the Ras-raf-1-ELK3 signaling pathway.
Ma S; Wang H; Li W; Yan Z; Luo X; Lu P
Nucleosides Nucleotides Nucleic Acids; 2022; 41(10):972-981. PubMed ID: 35737446
[TBL] [Abstract] [Full Text] [Related]
13. Infantile metastatic ependymoma with a novel molecular profile and favorable outcome to intensive chemotherapy without irradiation: Case-based review.
De Faria FW; Schieffer KM; Pierson CR; Boue DR; LaHaye S; Miller KE; Amayiri N; Koboldt DC; Lichtenberg T; Leraas K; Brennan P; Kelly B; White P; Magrini V; Wilson RK; Mardis ER; Cottrell CE; Rusin J; Finlay JL; Osorio DS
Genes Chromosomes Cancer; 2023 Jan; 62(1):39-46. PubMed ID: 35716171
[TBL] [Abstract] [Full Text] [Related]
14. Oncogenic Fusions in Gliomas: An Institutional Experience.
Polivka J; Svajdler M; Priban V; Mracek J; Kasik P; Martinek P; Ptakova N; Sharif Bagheri M; Shetti D; Pesta M; Potuznik P; Topolcan O
Anticancer Res; 2022 Apr; 42(4):1933-1939. PubMed ID: 35347013
[TBL] [Abstract] [Full Text] [Related]
15. HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma.
Sasame J; Ikegaya N; Kawazu M; Natsumeda M; Hayashi T; Isoda M; Satomi K; Tomiyama A; Oshima A; Honma H; Miyake Y; Takabayashi K; Nakamura T; Ueno T; Matsushita Y; Iwashita H; Kanemaru Y; Murata H; Ryo A; Terashima K; Yamanaka S; Fujii Y; Mano H; Komori T; Ichimura K; Cahill DP; Wakimoto H; Yamamoto T; Tateishi K
Clin Cancer Res; 2022 Jun; 28(11):2425-2439. PubMed ID: 35344043
[TBL] [Abstract] [Full Text] [Related]
16. BRAF Inhibitors Reprogram Cancer-Associated Fibroblasts to Drive Matrix Remodeling and Therapeutic Escape in Melanoma.
Liu T; Zhou L; Xiao Y; Andl T; Zhang Y
Cancer Res; 2022 Feb; 82(3):419-432. PubMed ID: 35064015
[TBL] [Abstract] [Full Text] [Related]
17. Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF
Schreck KC; Morin A; Zhao G; Allen AN; Flannery P; Glantz M; Green AL; Jones C; Jones KL; Kilburn LB; Nazemi KJ; Samuel D; Sanford B; Solomon DA; Wang J; Pratilas CA; Nicolaides T; Mulcahy Levy JM
Clin Cancer Res; 2021 Nov; 27(22):6197-6208. PubMed ID: 34433654
[TBL] [Abstract] [Full Text] [Related]
18. Promising potential of boron compounds against Glioblastoma: In Vitro antioxidant, anti-inflammatory and anticancer studies.
Turkez H; Arslan ME; Tatar A; Mardinoglu A
Neurochem Int; 2021 Oct; 149():105137. PubMed ID: 34293392
[TBL] [Abstract] [Full Text] [Related]
19. miR-424 induces apoptosis in glioblastoma cells and targets AKT1 and raf1 oncogenes from the ERBB signaling pathway.
Gheidari F; Arefian E; Adegani FJ; Kalhori MR; Seyedjafari E; Kabiri M; Teimoori-Toolabi L; Soleimani M
Eur J Pharmacol; 2021 Sep; 906():174273. PubMed ID: 34153339
[TBL] [Abstract] [Full Text] [Related]
20. Targetable BRAF and raf1 Alterations in Advanced Pediatric Cancers.
Rankin A; Johnson A; Roos A; Kannan G; Knipstein J; Britt N; Rosenzweig M; Haberberger J; Pavlick D; Severson E; Vergilio JA; Squillace R; Erlich R; Sathyan P; Cramer S; Kram D; Ross J; Miller V; Reddy P; Alexander B; Ali SM; Ramkissoon S
Oncologist; 2021 Jan; 26(1):e153-e163. PubMed ID: 32918774
[TBL] [Abstract] [Full Text] [Related]
[Next]
